ClinicalTrials.gg
CompletedNCT02065570Updated Feb 18, 2021Results posted

Study to Evaluate Efficacy and Safety of Two Drug Regimens in Subjects With Moderate to Severe Crohn's Disease

A Phase 3 interventional study of Adalimumab and Placebo in Crohn's Disease, sponsored by AbbVie. Completed at 143 sites in 20 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-02-18.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
514
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 42 studies testing adalimumab in Crohn Disease — 4 open to participants now, 5 under way, none of them phase 3. Adalimumab · Crohn Disease.

Enrollment
5th of 42
514 · median 143
Started
2014
with 3 others
Phase 3
22 of 42
none open now
Registered
26th of 42
by date
Lead sponsor
6 of 42
AbbVie

Among the 42 studies testing adalimumab in Crohn Disease, this one is the 5th largest by enrollment, is one of 4 that started in 2014, is one of 22 in phase 3, and was the 26th registered.

Crohn Disease

1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

4 of the 42 studies testing adalimumab in Crohn Disease are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About adalimumab

Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies testing adalimumab in Crohn Disease, or all of them as a file.
02

Study summary

This study will evaluate higher versus standard adalimumab dosing regimens for induction and maintenance therapy in subjects with moderately to severely active Crohn's Disease and evidence of mucosal ulceration.

03

Conditions studied

  • Crohn's Disease

Browse trials for

Keywords

  • Crohn's Disease
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of Crohn's disease (CD) for at least 90 days, confirmed by endoscopy during the Screening Period.
  • Active CD with a Crohn's Disease Activity Index (CDAI) despite treatment with oral and/or .
  • Mucosal ulceration on endoscopy.

Exclusion criteria

Exclusion Criteria:

  • Subject with ulcerative colitis or indeterminate colitis.
  • Subject who has had surgical bowel resections in the past 6 months or is planning resection.
  • Subjects with an ostomy or ileoanal pouch.
  • Subject with symptomatic bowel stricture or abdominal or peri-anal abcess.
  • Subject who has short bowel syndrome.
  • Chronic recurring infections or active Tuberculosis (TB).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
514 participants (actual)

Study arms

  • Experimental
    Induction: Standard Induction Dose

    Participants randomized to receive received blinded adalimumab 160 mg at Baseline and matching placebo at Week 1, adalimumab 80 mg and matching placebo at Week 2, matching placebo at Week 3, and then adalimumab 40 mg every other week (eow) starting at Week 4 through Week 12.

    Drug: Adalimumab · Drug: Placebo

  • Experimental
    Induction: Higher Induction Dose

    Participants randomized to receive blinded adalimumab 160 mg at Baseline, Week 1, Week 2, and Week 3. At Week 4, participants receive adalimumab 40 mg eow through Week 12.

    Drug: Adalimumab

  • Experimental
    Maintenance: Clinically Adjusted (CA) Regimen

    Participants randomized to the CA regimen receive adalimumab 40 mg eow beginning at Week 12. The adalimumab dose will be escalated to every week (ew) starting as early as Week 14 and up to Week 54 based on Crohn's Disease Activity Index (CDAI) or high-sensitivity C-reactive protein (hs-CRP) values, using results from the prior or current study visit. Once participants in the CA regimen are escalated, they remain on adalimumab 40 mg ew dosing.

    Drug: Adalimumab

  • Experimental
    Maintenance: Therapeutic Drug Monitoring (TDM) Regimen

    At Weeks 14, 28 and 42, the adalimumab dose for participants randomized to the TDM will be determined by protocol-established dose adjustment criteria. Doses will be determined using blinded serum concentrations at the prior visit (Weeks 12, 26 and 40, respectively) as well as the CDAI or hs-CRP values from the current or prior study visit. Participants who meet criteria for dose escalation at Weeks 14, 28 or 42 will receive 40 mg ew.

    Drug: Adalimumab

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Achieved Clinical Remission at Week 4

    Crohn's Disease Activity Index (CDAI) is used to assess the symptoms of participants with Crohn's Disease. Scores generally range from 0 to 600, where clinical remission of Crohn's disease is defined as CDAI \< 150, and very severe disease is defined as CDAI \> 450.

    Time frame: Week 4

  2. Percentage of Participants With Endoscopic Response at Week 12

    Endoscopic response was scored using the Simplified Endoscopic Score for Crohn's Disease (SES-CD). The SES-CD evaluates 4 endoscopic variables (ulcer size ranging from 0 \[none\] to 3 \[very large\]; ulcerated surface ranging from 0 \[none\] to 3 \[\>30%\]; affected surface ranging from 0 \[none\] to 3 \[\>75%\], and narrowing ranging from 0 \[none\] to 3 \[cannot be passed\]) in 5 segments assessed during ileocolonoscopy (ileum, right colon, transverse colon, sigmoid and left colon, and rectum). The total score is the sum of the 4 endoscopic variable scores and range from 0 to 56, where higher scores indicate more severe disease. Endoscopic response was defined as SES-CD total score \> 50% from Baseline (or for a Baseline SES-CD of 4, at least a 2 point reduction from Baseline) at Week 12.

    Time frame: Week 12

  3. Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

    Adverse event (AE): any untoward medical occurrence that does not necessarily have a causal relationship with this treatment. The investigator assessed the relationship of each event to the use of study drug as either probably related, possibly related, probably not related or not related. Serious AE (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the subject and may require medical or surgical intervention to prevent any of the outcomes listed above. TEAEs: any event that began or worsened in severity after the first dose of study drug in the induction or maintenance study. Events with unknown severity were counted as severe. Events with unknown relationship to study drug were counted as drug-related.

    Time frame: From first dose of study drug until 70 days following last dose of study drug in the induction study (up to 12 weeks) or maintenance study (up to 56 weeks).

Secondary outcomes

  1. Percentage of Participants With Sustained Clinical Remission (Per CDAI) at Both Weeks 4 and 12

    CDAI is used to assess the symptoms of participants with Crohn's Disease. Scores generally range from 0 to 600, where clinical remission of Crohn's disease is defined as CDAI \< 150, and very severe disease is defined as CDAI \> 450.

    Time frame: Week 4 and Week 12

  2. Percentage of Participants Who Achieve Clinical Response at Week 4 and Endoscopic Response at Week 12

    Clinical response was scored using CDAI, which assesses the symptoms of participants with Crohn's Disease. Scores generally range from 0 to 600, where clinical remission of Crohn's disease is defined as CDAI \< 150, and very severe disease is defined as CDAI \> 450. Clinical response was defined as a decrease in CDAI ≥ 70 points from Baseline. Endoscopic response was scored using the SES-CD, which evaluates 4 endoscopic variables (ulcer size ranging from 0 \[none\] to 3 \[very large\]; ulcerated surface ranging from 0 \[none\] to 3 \[\>30%\]; affected surface ranging from 0 \[none\] to 3 \[\>75%\], and narrowing ranging from 0 \[none\] to 3 \[cannot be passed\]) in 5 segments assessed during ileocolonoscopy. The total score is the sum of the 4 endoscopic variable scores and range from 0 to 56, where higher scores indicate more severe disease. Endoscopic response was defined as SES-CD total score \>50% from Baseline (or for Baseline SES-CD of 4, at least a 2-point reduction from Baseline) at Week 12.

    Time frame: Week 12

  3. Percentage of Participants With Clinical Remission at Week 12

    Clinical remission was scored using the CDAI. CDAI assesses the symptoms of participants with Crohn's Disease. Scores generally range from 0 to 600, where clinical remission of Crohn's disease is defined as CDAI \< 150, and very severe disease is defined as CDAI \> 450.

    Time frame: Week 12

  4. Percentage of Participants Who Discontinued Corticosteroid Use and Achieved Clinical Remission at Week 12 Among Participants Taking Corticosteroids at Baseline

    Clinical remission was scored using the CDAI. CDAI assesses the symptoms of participants with Crohn's Disease. Scores generally range from 0 to 600, where clinical remission of Crohn's disease is defined as CDAI \< 150, and very severe disease is defined as CDAI \> 450.

    Time frame: Week 12

  5. Percentage of Participants With Endoscopic Remission at Week 12

    Endoscopic remission was scored using the SES-CD.The SES-CD evaluates 4 endoscopic variables (ulcer size ranging from 0 \[none\] to 3 \[very large\]; ulcerated surface ranging from 0 \[none\] to 3 \[\>30%\]; affected surface ranging from 0 \[none\] to 3 \[\>75%\], and narrowing ranging from 0 \[none\] to 3 \[cannot be passed\]) in 5 segments assessed during ileocolonoscopy (ileum, right colon, transverse colon, sigmoid and left colon, and rectum). The total score is the sum of the 4 endoscopic variable scores and range from 0 to 56, where higher scores indicate more severe disease. Endoscopic remission was defined as SES-CD ≤ 4 and at least a 2-point reduction versus baseline and no subscore greater than 1 in any individual variable.

    Time frame: Week 12

  6. Change From Baseline in Fecal Calprotectin Level at Week 4

    Time frame: Baseline, Week 4

  7. Percentage of Participants With Hs-CRP < 5 mg/L and Fecal Calprotectin < 250 µg/g at Week 4

    Time frame: Week 4

  8. Percentage of Participants With Clinical Remission, Hs-CRP < 5 mg/L and Fecal Calprotectin < 250 µg/g at Week 4

    Clinical remission was scored using the CDAI. CDAI assesses the symptoms of participants with Crohn's Disease. Scores generally range from 0 to 600, where clinical remission of Crohn's disease is defined as CDAI \< 150, and very severe disease is defined as CDAI \> 450.

    Time frame: Week 4

  9. Percentage of Participants With Clinical Remission, Hs-CRP < 5 mg/L and Fecal Calprotectin < 250 µg/g and Endoscopic Remission at Week 12

    Clinical remission was scored using the CDAI. CDAI assesses the symptoms of participants with Crohn's Disease. Scores generally range from 0 to 600, where clinical remission of Crohn's disease is defined as CDAI \< 150, and very severe disease is defined as CDAI \> 450. Endoscopic remission was scored using the SES-CD.The SES-CD evaluates 4 endoscopic variables (ulcer size ranging from 0 \[none\] to 3 \[very large\]; ulcerated surface ranging from 0 \[none\] to 3 \[\>30%\]; affected surface ranging from 0 \[none\] to 3 \[\>75%\], and narrowing ranging from 0 \[none\] to 3 \[cannot be passed\]) in 5 segments assessed during ileocolonoscopy. The total score is the sum of the 4 endoscopic variable scores and range from 0 to 56, where higher scores indicate more severe disease. Endoscopic remission was defined as SES-CD ≤ 4 and at least a 2-point reduction versus baseline and no subscore greater than 1 in any individual variable.

    Time frame: Week 12

  10. Percentage of Participants Who Achieved an SES-CD ≤ 2 at Week 12

    The SES-CD evaluates 4 endoscopic variables (ulcer size ranging from 0 \[none\] to 3 \[very large\]; ulcerated surface ranging from 0 \[none\] to 3 \[\>30%\]; affected surface ranging from 0 \[none\] to 3 \[\>75%\], and narrowing ranging from 0 \[none\] to 3 \[cannot be passed\]) in 5 segments assessed during ileocolonoscopy (ileum, right colon, transverse colon, sigmoid and left colon, and rectum). The total score is the sum of the 4 endoscopic variable scores and range from 0 to 56, where higher scores indicate more severe disease.

    Time frame: Week 12

  11. Percentage of Participants With Clinical Response at Week 4

    Clinical response was scored using CDAI is used to assess the symptoms of participants with Crohn's Disease. Scores generally range from 0 to 600, where remission of Crohn's disease is defined as CDAI \< 150, and very severe disease is defined as CDAI \> 450. Clinical response was defined as a decrease in CDAI ≥ 70 points from baseline.

    Time frame: Week 4

  12. Percentage of Participants With Clinical Response at Week 12

    Clinical response was scored using CDAI. CDAI assesses the symptoms of participants with Crohn's Disease. Scores generally range from 0 to 600, where clinical remission of Crohn's disease is defined as CDAI \< 150, and very severe disease is defined as CDAI \> 450. Clinical response was defined as a decrease in CDAI ≥ 70 points from Baseline.

    Time frame: Week 12

  13. Percentage of Participants Achieving Response in Inflammatory Bowel Disease Questionnaire (IBDQ) Bowel Symptom Domain at Week 4

    The IBDQ is a self-administered 32-item questionnaire to evaluate quality of life across 4 dimensional scores: bowel, systemic, social and emotional. Responses to each question range from 1 (severe problem) to 7 (normal health). The range for Bowel Symptom domain score is 10 (severe problem) to 70 (normal health). Response in IBDQ Bowel Symptom domain is defined as an increase of IBDQ Bowel Symptom domain score ≥ 8.

    Time frame: Week 4

  14. Percentage of Participants Achieving Response in IBDQ Bowel Symptom Domain at Week 12

    The IBDQ is a self-administered 32-item questionnaire to evaluate quality of life across 4 dimensional scores: bowel, systemic, social and emotional. Responses to each question range from 1 (severe problem) to 7 (normal health). The range for Bowel Symptom domain score is 10 (severe problem) to 70 (normal health). Response in IBDQ Bowel Symptom domain is defined as an increase of IBDQ Bowel Symptom domain score ≥ 8.

    Time frame: Week 12

  15. Percentage of Participants Achieving Response in IBDQ Fatigue Item at Week 12

    The IBDQ is a self-administered 32-item questionnaire to evaluate quality of life across 4 dimensional scores: bowel, systemic, social and emotional. Responses to each question range from 1 (severe problem) to 7 (normal health). The IBDQ Fatigue item score range is from 1 (severe problem) to 7 (normal health). Response is defined as an increase of IBDQ Fatigue item score ≥ 1.

    Time frame: Week 12

07

Results

Posted Feb 18, 2021

Participant flow

Induction Study
Participant flow — Induction Study
MilestoneInduction: Standard Induction DoseInduction: Higher Induction DoseMaintenance: Clinically Adjusted (CA) RegimenMaintenance: Therapeutic Drug Monitoring (TDM) Regimen
Started20630800
Completed19228700
Not completed142100
Withdrew: Adverse event51200
Withdrew: Withdrawal by subject2300
Withdrew: Lost to follow-up1100
Withdrew: Other, not specified6500
Maintenance Study
Participant flow — Maintenance Study
MilestoneInduction: Standard Induction DoseInduction: Higher Induction DoseMaintenance: Clinically Adjusted (CA) RegimenMaintenance: Therapeutic Drug Monitoring (TDM) Regimen
Started00109109
Completed008790
Not completed002219
Withdrew: Adverse event0088
Withdrew: Withdrawal by subject0014
Withdrew: Lost to follow-up0022
Withdrew: Other, not specified00115

Outcome measures

PrimaryPercentage of Participants Who Achieved Clinical Remission at Week 4

Crohn's Disease Activity Index (CDAI) is used to assess the symptoms of participants with Crohn's Disease. Scores generally range from 0 to 600, where clinical remission of Crohn's disease is defined as CDAI \< 150, and very severe disease is defined as CDAI \> 450.

Time frame:
Week 4
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Clinical Remission at Week 4
percentage of participantsInduction: Standard Induction DoseInduction: Higher Induction Dose
Percentage of Participants Who Achieved Clinical Remission at Week 443.743.5
Statistical analysis
  • Induction: Standard Induction Dose vs Induction: Higher Induction Dose · Cochran-Mantel-Haenszel · p = 0.939 (Adjusted for previous infliximab use (or prior anti-tumor necrosis factor (TNF) use for participants randomized under original protocol), hs-CRP at Baseline (\<10 mg/L, \>=10 mg/L) and Crohn's disease severity at Baseline (CDAI ≤ 300, CDAI \> 300).) · Adjusted risk difference: 0.3 · 95% CI -8.1 to 8.8Risk difference = (adalimumab higher induction dose - adalimumab standard induction dose).
PrimaryPercentage of Participants With Endoscopic Response at Week 12

Endoscopic response was scored using the Simplified Endoscopic Score for Crohn's Disease (SES-CD). The SES-CD evaluates 4 endoscopic variables (ulcer size ranging from 0 \[none\] to 3 \[very large\]; ulcerated surface ranging from 0 \[none\] to 3 \[\>30%\]; affected surface ranging from 0 \[none\] to 3 \[\>75%\], and narrowing ranging from 0 \[none\] to 3 \[cannot be passed\]) in 5 segments assessed during ileocolonoscopy (ileum, right colon, transverse colon, sigmoid and left colon, and rectum). The total score is the sum of the 4 endoscopic variable scores and range from 0 to 56, where higher scores indicate more severe disease. Endoscopic response was defined as SES-CD total score \> 50% from Baseline (or for a Baseline SES-CD of 4, at least a 2 point reduction from Baseline) at Week 12.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With Endoscopic Response at Week 12
percentage of participantsInduction: Standard Induction DoseInduction: Higher Induction Dose
Percentage of Participants With Endoscopic Response at Week 1239.342.9
Statistical analysis
  • Induction: Standard Induction Dose vs Induction: Higher Induction Dose · Cochran-Mantel-Haenszel · p = 0.462 (Adjusted for previous infliximab use (or prior anti-TNF use for participants randomized under original protocol), hs-CRP at Baseline (\<10 mg/L, \>=10 mg/L) and Crohn's disease severity at Baseline (CDAI ≤ 300, CDAI \> 300).) · Adjusted risk difference: 3.2 · 95% CI -5.3 to 11.7Risk difference = (adalimumab higher induction dose - adalimumab standard induction dose).
PrimaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs)

Adverse event (AE): any untoward medical occurrence that does not necessarily have a causal relationship with this treatment. The investigator assessed the relationship of each event to the use of study drug as either probably related, possibly related, probably not related or not related. Serious AE (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the subject and may require medical or surgical intervention to prevent any of the outcomes listed above. TEAEs: any event that began or worsened in severity after the first dose of study drug in the induction or maintenance study. Events with unknown severity were counted as severe. Events with unknown relationship to study drug were counted as drug-related.

Time frame:
From first dose of study drug until 70 days following last dose of study drug in the induction study (up to 12 weeks) or maintenance study (up to 56 weeks).
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
ParticipantsInduction: Standard Induction DoseInduction: Higher Induction DoseMaintenance: Clinically Adjusted (CA) RegimenMaintenance: Therapeutic Drug Monitoring (TDM) Regimen
Any TEAE1331857776
TEAE w/reasonable possibility of being related to study drug54752933
Any severe TEAE131776
Any SAE101457
Any TEAE leading to discontinuation of study drug81389
Any TEAE leading to death0000
Deaths0000
SecondaryPercentage of Participants With Sustained Clinical Remission (Per CDAI) at Both Weeks 4 and 12

CDAI is used to assess the symptoms of participants with Crohn's Disease. Scores generally range from 0 to 600, where clinical remission of Crohn's disease is defined as CDAI \< 150, and very severe disease is defined as CDAI \> 450.

Time frame:
Week 4 and Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With Sustained Clinical Remission (Per CDAI) at Both Weeks 4 and 12
percentage of participantsInduction: Standard Induction DoseInduction: Higher Induction Dose
Percentage of Participants With Sustained Clinical Remission (Per CDAI) at Both Weeks 4 and 1235.039.0
Statistical analysis
  • Induction: Standard Induction Dose vs Induction: Higher Induction Dose · Cochran-Mantel-Haenszel · p = 0.269 (Adjusted for previous infliximab use (or prior anti-TNF use for participants randomized under original protocol), hs-CRP at Baseline (\<10 mg/L, \>=10 mg/L) and Crohn's disease severity at Baseline (CDAI ≤ 300, CDAI \> 300).) · Adjusted risk difference: 4.6 · 95% CI -3.6 to 12.8Risk difference = (adalimumab higher induction dose - adalimumab standard induction dose).
SecondaryPercentage of Participants Who Achieve Clinical Response at Week 4 and Endoscopic Response at Week 12

Clinical response was scored using CDAI, which assesses the symptoms of participants with Crohn's Disease. Scores generally range from 0 to 600, where clinical remission of Crohn's disease is defined as CDAI \< 150, and very severe disease is defined as CDAI \> 450. Clinical response was defined as a decrease in CDAI ≥ 70 points from Baseline. Endoscopic response was scored using the SES-CD, which evaluates 4 endoscopic variables (ulcer size ranging from 0 \[none\] to 3 \[very large\]; ulcerated surface ranging from 0 \[none\] to 3 \[\>30%\]; affected surface ranging from 0 \[none\] to 3 \[\>75%\], and narrowing ranging from 0 \[none\] to 3 \[cannot be passed\]) in 5 segments assessed during ileocolonoscopy. The total score is the sum of the 4 endoscopic variable scores and range from 0 to 56, where higher scores indicate more severe disease. Endoscopic response was defined as SES-CD total score \>50% from Baseline (or for Baseline SES-CD of 4, at least a 2-point reduction from Baseline) at Week 12.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieve Clinical Response at Week 4 and Endoscopic Response at Week 12
percentage of participantsInduction: Standard Induction DoseInduction: Higher Induction Dose
Percentage of Participants Who Achieve Clinical Response at Week 4 and Endoscopic Response at Week 1220.422.1
Statistical analysis
  • Induction: Standard Induction Dose vs Induction: Higher Induction Dose · Cochran-Mantel-Haenszel · p = 0.610 (Adjusted for previous infliximab use (or prior anti-TNF use for participants randomized under original protocol), hs-CRP at Baseline (\<10 mg/L, \>=10 mg/L) and Crohn's disease severity at Baseline (CDAI ≤ 300, CDAI \> 300).) · Adjusted risk difference: 1.8 · 95% CI -5.1 to 8.7Risk difference = (adalimumab higher induction dose - adalimumab standard induction dose).
SecondaryPercentage of Participants With Clinical Remission at Week 12

Clinical remission was scored using the CDAI. CDAI assesses the symptoms of participants with Crohn's Disease. Scores generally range from 0 to 600, where clinical remission of Crohn's disease is defined as CDAI \< 150, and very severe disease is defined as CDAI \> 450.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With Clinical Remission at Week 12
percentage of participantsInduction: Standard Induction DoseInduction: Higher Induction Dose
Percentage of Participants With Clinical Remission at Week 1251.562.3
Statistical analysis
  • Induction: Standard Induction Dose vs Induction: Higher Induction Dose · Cochran-Mantel-Haenszel · p = 0.008 (Adjusted for previous infliximab use (or prior anti-TNF use for participants randomized under original protocol), hs-CRP at Baseline (\<10 mg/L, \>=10 mg/L) and Crohn's disease severity at Baseline (CDAI ≤ 300, CDAI \> 300).) · Adjusted risk difference: 11.2 · 95% CI 2.9 to 19.6Risk difference = (adalimumab higher induction dose - adalimumab standard induction dose).
SecondaryPercentage of Participants Who Discontinued Corticosteroid Use and Achieved Clinical Remission at Week 12 Among Participants Taking Corticosteroids at Baseline

Clinical remission was scored using the CDAI. CDAI assesses the symptoms of participants with Crohn's Disease. Scores generally range from 0 to 600, where clinical remission of Crohn's disease is defined as CDAI \< 150, and very severe disease is defined as CDAI \> 450.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Who Discontinued Corticosteroid Use and Achieved Clinical Remission at Week 12 Among Participants Taking Corticosteroids at Baseline
percentage of participantsInduction: Standard Induction DoseInduction: Higher Induction Dose
Percentage of Participants Who Discontinued Corticosteroid Use and Achieved Clinical Remission at Week 12 Among Participants Taking Corticosteroids at Baseline48.052.9
Statistical analysis
  • Induction: Standard Induction Dose vs Induction: Higher Induction Dose · Cochran-Mantel-Haenszel · p = 0.336 (Adjusted for previous infliximab use (or prior anti-TNF use for participants randomized under original protocol), hs-CRP at Baseline (\<10 mg/L, \>=10 mg/L) and Crohn's disease severity at Baseline (CDAI ≤ 300, CDAI \> 300).) · Adjusted risk difference: 6.0 · 95% CI -6.2 to 18.2Risk difference = (adalimumab higher induction dose - adalimumab standard induction dose).
SecondaryPercentage of Participants With Endoscopic Remission at Week 12

Endoscopic remission was scored using the SES-CD.The SES-CD evaluates 4 endoscopic variables (ulcer size ranging from 0 \[none\] to 3 \[very large\]; ulcerated surface ranging from 0 \[none\] to 3 \[\>30%\]; affected surface ranging from 0 \[none\] to 3 \[\>75%\], and narrowing ranging from 0 \[none\] to 3 \[cannot be passed\]) in 5 segments assessed during ileocolonoscopy (ileum, right colon, transverse colon, sigmoid and left colon, and rectum). The total score is the sum of the 4 endoscopic variable scores and range from 0 to 56, where higher scores indicate more severe disease. Endoscopic remission was defined as SES-CD ≤ 4 and at least a 2-point reduction versus baseline and no subscore greater than 1 in any individual variable.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With Endoscopic Remission at Week 12
percentage of participantsInduction: Standard Induction DoseInduction: Higher Induction Dose
Percentage of Participants With Endoscopic Remission at Week 1226.228.6
Statistical analysis
  • Induction: Standard Induction Dose vs Induction: Higher Induction Dose · Cochran-Mantel-Haenszel · p = 0.694 (Adjusted for previous infliximab use (or prior anti-TNF use for participants randomized under original protocol), hs-CRP at Baseline (\<10 mg/L, \>=10 mg/L) and Crohn's disease severity at Baseline (CDAI ≤ 300, CDAI \> 300).) · Adjusted risk difference: 1.5 · 95% CI -6.1 to 9.1Risk difference = (adalimumab higher induction dose - adalimumab standard induction dose).
SecondaryChange From Baseline in Fecal Calprotectin Level at Week 4
Time frame:
Baseline, Week 4
Reported as:
Mean · µg/g
Change From Baseline in Fecal Calprotectin Level at Week 4
µg/gInduction: Standard Induction DoseInduction: Higher Induction Dose
Change From Baseline in Fecal Calprotectin Level at Week 4-1045.7 ± 1648.51-1157.0 ± 2000.69
Statistical analysis
  • Induction: Standard Induction Dose vs Induction: Higher Induction Dose · Cochran-Mantel-Haenszel · p = 0.946 · Ls mean of difference: 6.8 · 95% CI -192.3 to 205.9
SecondaryPercentage of Participants With Hs-CRP < 5 mg/L and Fecal Calprotectin < 250 µg/g at Week 4
Time frame:
Week 4
Reported as:
Number · percentage of participants
Percentage of Participants With Hs-CRP < 5 mg/L and Fecal Calprotectin < 250 µg/g at Week 4
percentage of participantsInduction: Standard Induction DoseInduction: Higher Induction Dose
Percentage of Participants With Hs-CRP < 5 mg/L and Fecal Calprotectin < 250 µg/g at Week 427.732.5
Statistical analysis
  • Induction: Standard Induction Dose vs Induction: Higher Induction Dose · Cochran-Mantel-Haenszel · p = 0.293 (Adjusted for previous infliximab use (or prior anti-TNF use for participants randomized under original protocol), hs-CRP at Baseline (\<10 mg/L, \>=10 mg/L) and Crohn's disease severity at Baseline (CDAI ≤ 300, CDAI \> 300).) · Adjusted risk difference: 4.0 · 95% CI -3.5 to 11.5Risk difference = (adalimumab higher induction dose - adalimumab standard induction dose).
SecondaryPercentage of Participants With Clinical Remission, Hs-CRP < 5 mg/L and Fecal Calprotectin < 250 µg/g at Week 4

Clinical remission was scored using the CDAI. CDAI assesses the symptoms of participants with Crohn's Disease. Scores generally range from 0 to 600, where clinical remission of Crohn's disease is defined as CDAI \< 150, and very severe disease is defined as CDAI \> 450.

Time frame:
Week 4
Reported as:
Number · percentage of participants
Percentage of Participants With Clinical Remission, Hs-CRP < 5 mg/L and Fecal Calprotectin < 250 µg/g at Week 4
percentage of participantsInduction: Standard Induction DoseInduction: Higher Induction Dose
Percentage of Participants With Clinical Remission, Hs-CRP < 5 mg/L and Fecal Calprotectin < 250 µg/g at Week 411.214.3
Statistical analysis
  • Induction: Standard Induction Dose vs Induction: Higher Induction Dose · Cochran-Mantel-Haenszel · p = 0.304 (Adjusted for previous infliximab use (or prior anti-TNF use for participants randomized under original protocol), hs-CRP at Baseline (\<10 mg/L, \>=10 mg/L) and Crohn's disease severity at Baseline (CDAI ≤ 300, CDAI \> 300).) · Adjusted risk difference: 3.0 · 95% CI -2.7 to 8.6Risk difference = (adalimumab higher induction dose - adalimumab standard induction dose).
SecondaryPercentage of Participants With Clinical Remission, Hs-CRP < 5 mg/L and Fecal Calprotectin < 250 µg/g and Endoscopic Remission at Week 12

Clinical remission was scored using the CDAI. CDAI assesses the symptoms of participants with Crohn's Disease. Scores generally range from 0 to 600, where clinical remission of Crohn's disease is defined as CDAI \< 150, and very severe disease is defined as CDAI \> 450. Endoscopic remission was scored using the SES-CD.The SES-CD evaluates 4 endoscopic variables (ulcer size ranging from 0 \[none\] to 3 \[very large\]; ulcerated surface ranging from 0 \[none\] to 3 \[\>30%\]; affected surface ranging from 0 \[none\] to 3 \[\>75%\], and narrowing ranging from 0 \[none\] to 3 \[cannot be passed\]) in 5 segments assessed during ileocolonoscopy. The total score is the sum of the 4 endoscopic variable scores and range from 0 to 56, where higher scores indicate more severe disease. Endoscopic remission was defined as SES-CD ≤ 4 and at least a 2-point reduction versus baseline and no subscore greater than 1 in any individual variable.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With Clinical Remission, Hs-CRP < 5 mg/L and Fecal Calprotectin < 250 µg/g and Endoscopic Remission at Week 12
percentage of participantsInduction: Standard Induction DoseInduction: Higher Induction Dose
Percentage of Participants With Clinical Remission, Hs-CRP < 5 mg/L and Fecal Calprotectin < 250 µg/g and Endoscopic Remission at Week 127.311.7
Statistical analysis
  • Induction: Standard Induction Dose vs Induction: Higher Induction Dose · Cochran-Mantel-Haenszel · p = 0.092 (Adjusted for previous infliximab use (or prior anti-TNF use for participants randomized under original protocol), hs-CRP at Baseline (\<10 mg/L, \>=10 mg/L) and Crohn's disease severity at Baseline (CDAI ≤ 300, CDAI \> 300).) · Adjusted risk difference: 4.2 · 95% CI -0.7 to 9.1Risk difference = (adalimumab higher induction dose - adalimumab standard induction dose).
SecondaryPercentage of Participants Who Achieved an SES-CD ≤ 2 at Week 12

The SES-CD evaluates 4 endoscopic variables (ulcer size ranging from 0 \[none\] to 3 \[very large\]; ulcerated surface ranging from 0 \[none\] to 3 \[\>30%\]; affected surface ranging from 0 \[none\] to 3 \[\>75%\], and narrowing ranging from 0 \[none\] to 3 \[cannot be passed\]) in 5 segments assessed during ileocolonoscopy (ileum, right colon, transverse colon, sigmoid and left colon, and rectum). The total score is the sum of the 4 endoscopic variable scores and range from 0 to 56, where higher scores indicate more severe disease.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved an SES-CD ≤ 2 at Week 12
percentage of participantsInduction: Standard Induction DoseInduction: Higher Induction Dose
Percentage of Participants Who Achieved an SES-CD ≤ 2 at Week 1216.020.1
Statistical analysis
  • Induction: Standard Induction Dose vs Induction: Higher Induction Dose · Cochran-Mantel-Haenszel · p = 0.278 (Adjusted for previous infliximab use (or prior anti-TNF use for participants randomized under original protocol), hs-CRP at Baseline (\<10 mg/L, \>=10 mg/L) and Crohn's disease severity at Baseline (CDAI ≤ 300, CDAI \> 300).) · Adjusted risk difference: 3.6 · 95% CI -2.9 to 10.2Risk difference = (adalimumab higher induction dose - adalimumab standard induction dose).
SecondaryPercentage of Participants With Clinical Response at Week 4

Clinical response was scored using CDAI is used to assess the symptoms of participants with Crohn's Disease. Scores generally range from 0 to 600, where remission of Crohn's disease is defined as CDAI \< 150, and very severe disease is defined as CDAI \> 450. Clinical response was defined as a decrease in CDAI ≥ 70 points from baseline.

Time frame:
Week 4
Reported as:
Number · percentage of participants
Percentage of Participants With Clinical Response at Week 4
percentage of participantsInduction: Standard Induction DoseInduction: Higher Induction Dose
Percentage of Participants With Clinical Response at Week 470.974.4
Statistical analysis
  • Induction: Standard Induction Dose vs Induction: Higher Induction Dose · Cochran-Mantel-Haenszel · p = 0.353 (Adjusted for previous infliximab use (or prior anti-TNF use for participants randomized under original protocol), hs-CRP at Baseline (\<10 mg/L, \>=10 mg/L) and Crohn's disease severity at Baseline (CDAI ≤ 300, CDAI \> 300).) · Adjusted risk difference: 3.7 · 95% CI -4.1 to 11.5Risk difference = (adalimumab higher induction dose - adalimumab standard induction dose).
SecondaryPercentage of Participants With Clinical Response at Week 12

Clinical response was scored using CDAI. CDAI assesses the symptoms of participants with Crohn's Disease. Scores generally range from 0 to 600, where clinical remission of Crohn's disease is defined as CDAI \< 150, and very severe disease is defined as CDAI \> 450. Clinical response was defined as a decrease in CDAI ≥ 70 points from Baseline.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With Clinical Response at Week 12
percentage of participantsInduction: Standard Induction DoseInduction: Higher Induction Dose
Percentage of Participants With Clinical Response at Week 1274.883.4
Statistical analysis
  • Induction: Standard Induction Dose vs Induction: Higher Induction Dose · Cochran-Mantel-Haenszel · p = 0.015 (Adjusted for previous infliximab use (or prior anti-TNF use for participants randomized under original protocol), hs-CRP at Baseline (\<10 mg/L, \>=10 mg/L) and Crohn's disease severity at Baseline (CDAI ≤ 300, CDAI \> 300).) · Adjusted risk difference: 8.9 · 95% CI 1.8 to 16.0Risk difference = (adalimumab higher induction dose - adalimumab standard induction dose).
SecondaryPercentage of Participants Achieving Response in Inflammatory Bowel Disease Questionnaire (IBDQ) Bowel Symptom Domain at Week 4

The IBDQ is a self-administered 32-item questionnaire to evaluate quality of life across 4 dimensional scores: bowel, systemic, social and emotional. Responses to each question range from 1 (severe problem) to 7 (normal health). The range for Bowel Symptom domain score is 10 (severe problem) to 70 (normal health). Response in IBDQ Bowel Symptom domain is defined as an increase of IBDQ Bowel Symptom domain score ≥ 8.

Time frame:
Week 4
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Response in Inflammatory Bowel Disease Questionnaire (IBDQ) Bowel Symptom Domain at Week 4
percentage of participantsInduction: Standard Induction DoseInduction: Higher Induction Dose
Percentage of Participants Achieving Response in Inflammatory Bowel Disease Questionnaire (IBDQ) Bowel Symptom Domain at Week 471.474.7
Statistical analysis
  • Induction: Standard Induction Dose vs Induction: Higher Induction Dose · Cochran-Mantel-Haenszel · p = 0.394 (Adjusted for previous infliximab use (or prior anti-TNF use for participants randomized under original protocol), hs-CRP at Baseline (\<10 mg/L, \>=10 mg/L) and Crohn's disease severity at Baseline (CDAI ≤ 300, CDAI \> 300).) · Adjusted risk difference: 3.4 · 95% CI -4.4 to 11.1Risk difference = (adalimumab higher induction dose - adalimumab standard induction dose).
SecondaryPercentage of Participants Achieving Response in IBDQ Bowel Symptom Domain at Week 12

The IBDQ is a self-administered 32-item questionnaire to evaluate quality of life across 4 dimensional scores: bowel, systemic, social and emotional. Responses to each question range from 1 (severe problem) to 7 (normal health). The range for Bowel Symptom domain score is 10 (severe problem) to 70 (normal health). Response in IBDQ Bowel Symptom domain is defined as an increase of IBDQ Bowel Symptom domain score ≥ 8.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Response in IBDQ Bowel Symptom Domain at Week 12
percentage of participantsInduction: Standard Induction DoseInduction: Higher Induction Dose
Percentage of Participants Achieving Response in IBDQ Bowel Symptom Domain at Week 1273.376.9
Statistical analysis
  • Induction: Standard Induction Dose vs Induction: Higher Induction Dose · Cochran-Mantel-Haenszel · p = 0.349 (Adjusted for previous infliximab use (or prior anti-TNF use for participants randomized under original protocol), hs-CRP at Baseline (\<10 mg/L, \>=10 mg/L) and Crohn's disease severity at Baseline (CDAI ≤ 300, CDAI \> 300).) · Adjusted risk difference: 3.6 · 95% CI -4.0 to 11.2Risk difference = (adalimumab higher induction dose - adalimumab standard induction dose)
SecondaryPercentage of Participants Achieving Response in IBDQ Fatigue Item at Week 12

The IBDQ is a self-administered 32-item questionnaire to evaluate quality of life across 4 dimensional scores: bowel, systemic, social and emotional. Responses to each question range from 1 (severe problem) to 7 (normal health). The IBDQ Fatigue item score range is from 1 (severe problem) to 7 (normal health). Response is defined as an increase of IBDQ Fatigue item score ≥ 1.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Response in IBDQ Fatigue Item at Week 12
percentage of participantsInduction: Standard Induction DoseInduction: Higher Induction Dose
Percentage of Participants Achieving Response in IBDQ Fatigue Item at Week 1268.476.0
Statistical analysis
  • Induction: Standard Induction Dose vs Induction: Higher Induction Dose · Cochran-Mantel-Haenszel · p = 0.054 (Adjusted for previous infliximab use (or prior anti-TNF use for participants randomized under original protocol), hs-CRP at Baseline (\<10 mg/L, \>=10 mg/L) and Crohn's disease severity at Baseline (CDAI ≤ 300, CDAI \> 300).) · Adjusted risk difference: 7.6 · 95% CI -0.1 to 15.3Risk difference = (adalimumab higher induction dose - adalimumab standard induction dose)

Adverse events

Collected over From first dose of study drug until 70 days following last dose of study drug in the induction study (up to 12 weeks) or maintenance study (up to 56 weeks).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Induction: Standard Induction Dose0/206 (0%)10/206 (4.9%)54/206 (26.2%)
Induction: Higher Induction Dose0/308 (0%)14/308 (4.5%)58/308 (18.8%)
Maintenance: Clinically Adjusted (CA) Regimen0/109 (0%)5/109 (4.6%)41/109 (37.6%)
Maintenance: Therapeutic Drug Management (TDM) Regimen0/109 (0%)7/109 (6.4%)33/109 (30.3%)
Most frequent serious events
Showing 10 of 40
Most frequent serious events
EventInduction: Standard Induction DoseInduction: Higher Induction DoseMaintenance: Clinically Adjusted (CA) RegimenMaintenance: Therapeutic Drug Management (TDM) Regimen
CROHN'S DISEASEGastrointestinal disorders3/2063/3082/1091/109
SCLERITISEye disorders0/2060/3080/1091/109
UVEITISEye disorders0/2060/3080/1091/109
INTESTINAL HAEMORRHAGEGastrointestinal disorders0/2060/3080/1091/109
INTESTINAL OBSTRUCTIONGastrointestinal disorders0/2062/3081/1090/109
SMALL INTESTINAL OBSTRUCTIONGastrointestinal disorders1/2060/3081/1090/109
INFECTIOUS MONONUCLEOSISInfections and infestations0/2060/3080/1091/109
SEPSISInfections and infestations0/2060/3080/1091/109
URINARY TRACT INFECTIONInfections and infestations0/2061/3080/1091/109
VARICELLAInfections and infestations0/2060/3080/1091/109
Most frequent other events
Most frequent other events
EventInduction: Standard Induction DoseInduction: Higher Induction DoseMaintenance: Clinically Adjusted (CA) RegimenMaintenance: Therapeutic Drug Management (TDM) Regimen
CROHN'S DISEASEGastrointestinal disorders12/20614/30816/10915/109
NASOPHARYNGITISInfections and infestations9/20619/30815/10910/109
HEADACHENervous system disorders18/20617/3089/1098/109
ARTHRALGIAMusculoskeletal and connective tissue disorders16/20610/3088/1094/109
NAUSEAGastrointestinal disorders15/2069/3085/1093/109
DIARRHOEAGastrointestinal disorders3/2062/3086/1094/109
DIZZINESSNervous system disorders11/2062/3080/1090/109

Baseline characteristics

Age, Continuous
Age, Continuous(years)Induction: Standard Induction DoseInduction: Higher Induction DoseTotal
Mean36.4 ± 12.7936.4 ± 13.0236.4 ± 12.92
Sex: Female, Male
Sex: Female, Male(Participants)Induction: Standard Induction DoseInduction: Higher Induction DoseTotal
Female109158267
Male97150247
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Induction: Standard Induction DoseInduction: Higher Induction DoseTotal
Hispanic or Latino51015
Not Hispanic or Latino000
Unknown or Not Reported201298499
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Induction: Standard Induction DoseInduction: Higher Induction DoseTotal
American Indian or Alaska Native011
Asian5611
Native Hawaiian or Other Pacific Islander000
Black or African American181129
White182288470
More than one race112
Unknown or Not Reported011
08

Study locations

143 sites
  • Birmingham Gastroenterology Associates O.C /ID# 137282
    Birmingham, Alabama 35209, United States
  • Digestive Health Specialists of the Southeast /ID# 122483
    Dothan, Alabama 36305, United States
  • Moore UC San Diego Cancer Center /ID# 119053
    La Jolla, California 92093, United States
  • Axis Clinical Trials /ID# 130390
    Los Angeles, California 90036, United States
  • Rocky Mountain Gastroenterology /ID# 119038
    Wheat Ridge, Colorado 80033, United States
  • Medical Research Ctr CT /ID# 119037
    Hamden, Connecticut 06518, United States
  • Gastroenterology Group Naples /ID# 122493
    Naples, Florida 34102, United States
  • Internal Med Specialists /ID# 137737
    Orlando, Florida 32806, United States
  • Shafran Gastroenterology Ctr /ID# 119057
    Winter Park, Florida 32789, United States
  • Winship Cancer Institute of Emory University /ID# 136851
    Atlanta, Georgia 30322, United States
  • Atlanta Gastro Assoc /ID# 119065
    Atlanta, Georgia 30342, United States
  • Gastroenterology Associates of Central Georgia, LLC /ID# 119056
    Macon, Georgia 31201, United States
  • Northwestern University Feinberg School of Medicine /ID# 119043
    Chicago, Illinois 60611-2927, United States
  • University of Chicago DCAM /ID# 119077
    Chicago, Illinois 60637-1443, United States
  • Carle Foundation Hospital Digestive Health Research Center /ID# 136008
    Urbana, Illinois 61801, United States
  • Louisana Research Center, LLC /ID# 136749
    Shreveport, Louisiana 71105-6800, United States
  • Investigative Clinical Research /ID# 119033
    Annapolis, Maryland 21228, United States
  • MGG Group Co, Inc.Chevy Chase Clinical Research /ID# 119042
    Chevy Chase, Maryland 20815, United States
  • Commonwealth Clinical Studies /ID# 136850
    Brockton, Massachusetts 02302, United States
  • University of Michigan Health Systems /ID# 119076
    Ann Arbor, Michigan 48109, United States
  • Minnesota Gastroenterology, P. A. /ID# 137280
    Plymouth, Minnesota 55446, United States
  • Mayo Clinic /ID# 122489
    Rochester, Minnesota 55905-0001, United States
  • Kansas City Research Institute /ID# 119034
    Kansas City, Missouri 64131, United States
  • Ctr for Digest and Liver Dis /ID# 119040
    Mexico, Missouri 65265, United States
  • Albany Medical College /ID# 140200
    Albany, New York 12208, United States
  • NYU Langone Long Island Clinical Research Associates /ID# 119035
    Great Neck, New York 11021, United States
  • The Mount Sinai Hospital /ID# 127116
    New York, New York 10029, United States
  • Charlotte Gastroenterology and Hepatology, PLLC /ID# 119041
    Charlotte, North Carolina 28207, United States
  • Wake Research Associates, LLC /ID# 119029
    Raleigh, North Carolina 27612, United States
  • Consultants for Clinical Res /ID# 119052
    Cincinnati, Ohio 45219, United States
  • Gastro United of Tulsa /ID# 122485
    Tulsa, Oklahoma 74135, United States
  • The Oregon Clinic, Gastroenterology - West /ID# 135272
    Portland, Oregon 97225, United States
  • West Bay Clinical Research /ID# 138330
    Warwick, Rhode Island 02886, United States
  • Medical University of South Carolina /ID# 138122
    Charleston, South Carolina 29425, United States
  • Erlanger Institute for Clinical Research /ID# 129008
    Chattanooga, Tennessee 37403, United States
  • Gastro One /ID# 119068
    Germantown, Tennessee 38138, United States
  • Nashville Med Res Inst /ID# 119050
    Nashville, Tennessee 37205, United States
  • Vanderbilt Univ Med Ctr /ID# 125501
    Nashville, Tennessee 37232-0011, United States
  • Texas Digestive Disease Consultants - Dallas /ID# 138121
    Dallas, Texas 75231, United States
  • Baylor College of Medicine /ID# 137277
    Houston, Texas 77030-3411, United States
  • Austin Institute for Clinical Research /ID# 125500
    Pflugerville, Texas 78660, United States
  • Texas Digestive Disease Consultants - Southlake /ID# 137283
    Southlake, Texas 76092, United States
  • Advanced Research Institute /ID# 119048
    Ogden, Utah 84403, United States
  • University of Utah /ID# 119062
    Salt Lake City, Utah 84112-5500, United States
  • Gastro Assoc of Tidewater /ID# 135897
    Chesapeake, Virginia 23320, United States
  • New River Valley Research Inst /ID# 127807
    Christiansburg, Virginia 24073, United States
  • Wisconsin Center for Advanced Research, a division of GI Associates, LLC /ID# 119036
    Milwaukee, Wisconsin 53215, United States
  • Froedtert Memorial Lutheran Hospital /ID# 119081
    Milwaukee, Wisconsin 53226-3522, United States
  • KH der Elisabethinen Linz GmbH /ID# 126280
    Linz, Oberoesterreich 4010, Austria
  • Medizinische Universitat Wien /ID# 126279
    Vienna, Wien 1090, Austria
  • Medizinische Universitat Innsbruck,Universitatsklinik fur Innere Medizin 1 /ID# 126249
    Innsbruck, 6020, Austria
  • LKH Salzburg and Paracelsus /ID# 126248
    Salzburg, 5020, Austria
  • Krankenhaus der Barmherzigen Bruder /ID# 126270
    St Veit An Der Glan, 9300, Austria
  • AZ Maria Middelares /ID# 126194
    Ghent, 9000, Belgium
  • AZ Sint-Lucas /ID# 126242
    Ghent, 9000, Belgium
  • UZ Leuven /ID# 126240
    Leuven, 3000, Belgium
  • CHU de Liege /ID# 126241
    Liege, 4000, Belgium
  • AZ-Delta /ID# 126195
    Roeselare, 8800, Belgium
  • University of Calgary Cumming School of Medicine Adult Cystic Fibrosis Clinic /ID# 119017
    Calgary, Alberta T2N 4Z6, Canada
  • University of Alberta /ID# 119022
    Edmonton, Alberta T6G 2X8, Canada
  • Winnipeg Regional Health Authority /ID# 119015
    Winnipeg, Manitoba R3A 1R9, Canada
  • Qe Ii Hsc /Id# 127115
    Halifax, Nova Scotia B3H 1V7, Canada
  • London Health Sciences Centre - University Hospital /ID# 119026
    London, Ontario N6A 5A5, Canada
  • Medicor Research Inc /ID# 119024
    Sudbury, Ontario P3E 5M4, Canada
  • Toronto Digestive Disease Asso /ID# 119019
    Vaughan, Ontario L4L 4Y7, Canada
  • Montreal General Hospital - McGill University Health Center /ID# 119025
    Montreal, Quebec H3G 1A4, Canada
  • Fakultni Nemocnice Olomouc /ID# 126264
    Olomouc, Olomoucky Kraj 779 00, Czechia
  • Nemocnice Ceske Budejovice a.s. /ID# 126266
    Ceske Budejovice, 370 01, Czechia
  • Hepato-Gastroenterologie HK s.r.o. /ID# 126269
    Hradec Kralove, 500 12, Czechia
  • ISCARE a.s. /ID# 137977
    Praha 9, 190 00, Czechia
  • Krajska zdravotni a.s. Masarykova nemocnice v Usti nad Labem o.z. /ID# 138331
    Usti Nad Labem, 401 13, Czechia
  • Herlev Hospital /ID# 127741
    Herlev, Hovedstaden 2730, Denmark
  • Silkeborg Hospital /ID# 126251
    Silkeborg, 8600, Denmark
  • CHRU Lille - Hopital Claude Huriez /ID# 127743
    Lille CEDEX, Hauts-de-France 59045, France
  • CHU NANCY - Hopital Brabois Adultes /ID# 127742
    Vandoeuvre les Nancy CEDEX, Meurthe-et-Moselle 54511, France
  • CHU Amiens-Picardie Site Sud /ID# 126237
    Amiens CEDEX 1, Somme 80054, France
  • Centre Hospitalier Universitaire de Grenoble - Hopital Michallon /ID# 126200
    Grenoble, 38043, France
  • Hopital l'Archet 2 /ID# 126238
    Nice, 06202, France
  • CHU de Saint-Etienne, Hopital Nord /ID# 134450
    SAINT-ETIENNE Cedex 1, 42270, France
  • Hopital Rangueil /ID# 126239
    Toulouse, 31059, France
  • Universitaetsklinikum Schleswig-Holstein /ID# 126260
    Kiel, Schleswig-Holstein 24105, Germany
  • Charite Universitaetsmedizin Berlin /ID# 126196
    Berlin, 10117, Germany
  • Private Practice - Dr. Michael R. MroB Dipl. med. S. Schache /ID# 126257
    Berlin, 10318, Germany
  • Israelitisches Krankenhaus Hamburg /ID# 136549
    Hamburg, 22297, Germany
  • Asklepios Westklinikum Hamburg /ID# 126275
    Hamburg, 22559, Germany
  • Universitaetsklinikum Jena /ID# 126261
    Jena, 07747, Germany
  • EUGASTRO GmbH /ID# 126259
    Leipzig, 04103, Germany
  • Universitatsklinikum Magdeburg /ID# 126256
    Magdeburg, 39120, Germany
  • Gastro Campus Research GbR /ID# 126274
    Munster, 48159, Germany
  • Semmelweis Egyetem /ID# 137896
    Budapest, 1085, Hungary
  • Magyar Elhizastudomanyi KKft. /ID# 126276
    Budapest, 1124, Hungary
  • Pecsi Tudomanyegyetem Klinikai l.sz. Belgyogyaszati Klinika /ID# 137895
    Pecs, 7624, Hungary
  • University of Szeged /ID# 126263
    Szeged, 6720, Hungary
  • Rabin Medical Center /ID# 126198
    Petakh Tikva, Tel-Aviv 4941492, Israel
  • Soroka University Medical Center /ID# 126243
    Be'er Sheva, 84101, Israel
  • Gastroenterology Institute, Division of Medicine /ID# 126245
    Jerusalem, 91120, Israel
  • Kaplan Medical Center /ID# 126246
    Rehovot, 76100, Israel
  • UOSD - Azienda Ospedaliera San Camillo Forlanini /ID# 127745
    Rome, Lazio 00152, Italy
  • Policlinico Agostino Gemelli /ID# 127746
    Rome, Lazio 00168, Italy
  • Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico /ID# 126221
    Milan, Lombardia 20122, Italy

Showing the first 100 of 143 sites across 20 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • D'Haens GR, Sandborn WJ, Loftus EV Jr, Hanauer SB, Schreiber S, Peyrin-Biroulet L, Panaccione R, Panes J, Baert F, Colombel JF, Ferrante M, Louis E, Armuzzi A, Zhou Q, Goteti VS, Mostafa NM, Doan TT, Petersson J, Finney-Hayward T, Song AP, Robinson AM, Danese S. Higher vs Standard Adalimumab Induction Dosing Regimens and Two Maintenance Strategies: Randomized SERENE CD Trial Results. Gastroenterology. 2022 Jun;162(7):1876-1890. doi: 10.1053/j.gastro.2022.01.044. Epub 2022 Feb 3. PubMed 35122766 ↗
  • Greener T, Boland K, Milgrom R, Ben-Bassat O, Steinhart AH, Silverberg MS, Narula N. Higher adalimumab maintenance regimen is more effective than standard dose in anti-TNF experienced Crohn's disease patients. Eur J Gastroenterol Hepatol. 2021 Oct 1;33(10):1274-1279. doi: 10.1097/MEG.0000000000002250. PubMed 34402466 ↗

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.

Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.

Data sharing details ↗ · www.abbvie.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2014 to primary completion in Jan 2020, 68 months.

Results were first posted in Feb 2021, 1 year after primary completion.

Of 70 industry-sponsored phase 3 interventional studies under Crohn Disease, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 69. This study's 68 months is above that.

Counting every sponsor, half of 88 studies reached it within 49 months; a quarter within 36 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 17, 2014
First posted
Feb 19, 2014
StartActual
May 1, 2014
Primary completionActual
Jan 30, 2020
CompletionActual
Jan 30, 2020
Results first posted
Feb 18, 2021
Last update
Feb 18, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 18, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02065570
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Feb 19, 2014
Start date
May 1, 2014
Primary completion
Jan 30, 2020
Completion
Jan 30, 2020
Results posted
Feb 18, 2021
Last update
Feb 18, 2021

Study contacts

AbbVie Inc.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adalimumab

Start the discussion